{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:22:27Z","timestamp":1792142547548,"version":"4.4.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s13300-023-01423-3","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T17:01:17Z","timestamp":1685811677000},"page":"1299-1317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Effects of Second-Generation Versus Earlier Intermediate\/Basal Insulin Analogues on Rates of Hypoglycemia in Adults with Type 1 and 2 Diabetes (iNPHORM, US)"],"prefix":"10.1007","volume":"14","author":[{"given":"Jason E.","family":"Black","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart B.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget L.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria","family":"Ratzki-Leewing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,3]]},"reference":[{"key":"1423_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.170","author":"BM Frier","year":"2014","unstructured":"Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014. https:\/\/doi.org\/10.1038\/nrendo.2014.170.","journal-title":"Nat Rev Endocrinol"},{"key":"1423_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/SMJ.0b013e318182d8a2","volume":"102","author":"WC Hsu","year":"2009","unstructured":"Hsu WC. Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals. South Med J. 2009;102:67\u201376.","journal-title":"South Med J"},{"key":"1423_CR3","first-page":"186","volume":"29","author":"L Leiter","year":"2005","unstructured":"Leiter L, Yale J, Chiasson J, Harris S, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemic management. Can J Diabetes. 2005;29:186\u201392.","journal-title":"Can J Diabetes"},{"key":"1423_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jdiacomp.2006.02.004","volume":"21","author":"S Nakar","year":"2007","unstructured":"Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in Type 2 diabetes: family physicians\u2019 misconception of patients\u2019 fears contributes to existing barriers. J Diabetes Complications. 2007;21:220\u20136.","journal-title":"J Diabetes Complications"},{"key":"1423_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/0145721710388426","volume":"37","author":"RM Cuddihy","year":"2011","unstructured":"Cuddihy RM, Philis-Tsimikas A, Nazeri A. Type 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? Results from the MODIFY survey. Diabetes Educ. 2011;37:111\u201323.","journal-title":"Diabetes Educ"},{"key":"1423_CR6","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.2337\/dc14-0991","volume":"37","author":"MC Riddle","year":"2014","unstructured":"Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD. New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37:2755\u201362.","journal-title":"Diabetes Care"},{"key":"1423_CR7","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2337\/dc15-0249","volume":"38","author":"PD Home","year":"2015","unstructured":"Home PD, Bergenstal RM, Bolli GB, et al. New Insulin Glargine 300 Units\/mL Versus Glargine 100 Units\/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care. 2015;38:2217\u201325.","journal-title":"Diabetes Care"},{"key":"1423_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/dom.12485","volume":"17","author":"R Ritzel","year":"2015","unstructured":"Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U\/ml versus glargine 100 U\/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859\u201367.","journal-title":"Diabetes Obes Metab"},{"key":"1423_CR9","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/dom.12532","volume":"17","author":"H Yki-J\u00e4rvinen","year":"2015","unstructured":"Yki-J\u00e4rvinen H, Bergenstal RM, Bolli GB, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U\/ml versus insulin glargine 100 U\/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab. 2015;17:1142\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1423_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.diabres.2016.10.002","volume":"122","author":"M Matsuhisa","year":"2016","unstructured":"Matsuhisa M, Koyama M, Cheng X, et al. Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U\/mL compared with glargine 100U\/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension). Diabetes Res Clin Pract. 2016;122:133\u201340.","journal-title":"Diabetes Res Clin Pract"},{"key":"1423_CR11","first-page":"285","volume":"20","author":"HW Rodbard","year":"2014","unstructured":"Rodbard HW, Gough S, Lane W, Korsholm L, Bretler DM, Handelsman Y. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2014;20:285\u201392.","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"1423_CR12","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","volume":"379","author":"AJ Garber","year":"2012","unstructured":"Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet Lond Engl. 2012;379:1498\u2013507.","journal-title":"Lancet Lond Engl"},{"key":"1423_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/dom.12438","volume":"17","author":"GB Bolli","year":"2015","unstructured":"Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U\/ml compared with glargine 100 U\/ml in insulin-na\u00efve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17:386\u201394.","journal-title":"Diabetes Obes Metab"},{"key":"1423_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.2017.7117","volume":"318","author":"C Wysham","year":"2017","unstructured":"Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318:45\u201356.","journal-title":"JAMA"},{"key":"1423_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2017.7115","volume":"318","author":"W Lane","year":"2017","unstructured":"Lane W, Bailey TS, Gerety G, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017;318:33\u201344.","journal-title":"JAMA"},{"key":"1423_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1136\/bmjdrc-2017-000503","volume":"6","author":"A Ratzki-Leewing","year":"2018","unstructured":"Ratzki-Leewing A, Harris SB, Mequanint S, et al. Real-world crude incidence of hypoglycemia in adults with diabetes: Results of the InHypo-DM Study, Canada. BMJ Open Diabetes Res Care. 2018;6:503.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1423_CR17","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/dom.14264","volume":"23","author":"D Mauricio","year":"2021","unstructured":"Mauricio D, Westerbacka J, Nicholls C, Wu J, Gupta R, Eliasson B. How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U\/mL in a real-world setting? Diabetes Obes Metab. 2021;23:838\u201343.","journal-title":"Diabetes Obes Metab"},{"key":"1423_CR18","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1111\/dom.13345","volume":"20","author":"SD Sullivan","year":"2018","unstructured":"Sullivan SD, Bailey TS, Roussel R, et al. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units\/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes Obes Metab. 2018;20:2148.","journal-title":"Diabetes Obes Metab"},{"key":"1423_CR19","unstructured":"Bailey T, Zhou L, Gupta R, et al. E13: Glycemic goal attainment and hypoglycemia risk outcomes in patients with T2D initiating insulin glargine 300 U\/mL versus 100 U\/mL in real-world clinical practice. In: Poster J. Manag. Care Spec. Pharm. Conf. 2018."},{"key":"1423_CR20","unstructured":"Zhou FL, Ye F, Gupta V. LB SUN 81: lower risk of hypoglycemia after switch to insulin glargine 300 U\/mL (Gla-300) vs other basal insulins in patients with type 2 diabetes (T2D) on basal insulin in real-world clinical settings (Deliver 2 study). In: Endocr. Soc. 2017 Annu. Meet. 2017."},{"key":"1423_CR21","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1001\/jamainternmed.2018.1014","volume":"178","author":"AJ Karter","year":"2018","unstructured":"Karter AJ, Moffet HH, Liu JY, Lipska KJ. Surveillance of hypoglycemia-limitations of emergency department and hospital utilization data. JAMA Intern Med. 2018;178:987\u20138.","journal-title":"JAMA Intern Med"},{"key":"1423_CR22","unstructured":"Healthcare Effectiveness Data and Information Set. Emergency Department visits for hypoglycemia in older adults with diabetes (EDH): summary of changes to HEDIS. National Committee for Quality Assurance. 2023."},{"key":"1423_CR23","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","volume":"361","author":"RR Holman","year":"2009","unstructured":"Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736\u201347.","journal-title":"N Engl J Med"},{"key":"1423_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2337\/diacare.23.5.639","volume":"23","author":"RE Ratner","year":"2000","unstructured":"Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000;23:639\u201343.","journal-title":"Diabetes Care"},{"key":"1423_CR25","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.3399\/BJGP.2021.0581","volume":"72","author":"M Dankers","year":"2022","unstructured":"Dankers M, Hek K, Nelissen-Vrancken M, Houweling ST, Mantel-Teeuwisse A, van Dijk L. Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study. Br J Gen Pract J R Coll Gen Pract. 2022;72:e430\u20136.","journal-title":"Br J Gen Pract J R Coll Gen Pract"},{"key":"1423_CR26","doi-asserted-by":"publisher","DOI":"10.2196\/33726","author":"A Ratzki-Leewing","year":"2022","unstructured":"Ratzki-Leewing A, Ryan BL, Zou G, et al. Predicting real-world hypoglycemia risk in American adults with type 1 or 2 diabetes mellitus prescribed insulin and\/or secretagogues: Protocol for a prospective, 12-wave internet-based panel survey with email support (the iNPHORM study, USA). JMIR Res Protoc. 2022. https:\/\/doi.org\/10.2196\/33726.","journal-title":"JMIR Res Protoc"},{"key":"1423_CR27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/EDE.0b013e3181577654","volume":"18","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiol Camb Mass. 2007;18:800\u20134.","journal-title":"Epidemiol Camb Mass"},{"key":"1423_CR28","volume-title":"Transport survey quality and innovation","author":"N Kalfs","year":"2003","unstructured":"Kalfs N, Evert H van. Nonresponse and travel surveys. In: Transport survey quality and innovation. Elsevier; 2003."},{"key":"1423_CR29","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/EDE.0b013e318225c2be","volume":"22","author":"J Textor","year":"2011","unstructured":"Textor J, Hardt J, Kn\u00fcppel S. DAGitty: a graphical tool for analyzing causal diagrams. Epidemiol Camb Mass. 2011;22:745.","journal-title":"Epidemiol Camb Mass"},{"key":"1423_CR30","first-page":"11","volume":"37","author":"EL Johnson","year":"2019","unstructured":"Johnson EL, Feldman H, Butts A, et al. Standards of medical care in diabetes\u20142019 abridged for primary care providers. Clin Diabetes Publ Am Diabetes Assoc. 2019;37:11.","journal-title":"Clin Diabetes Publ Am Diabetes Assoc"},{"key":"1423_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/dc16-2215","volume":"40","author":"International Hypoglycaemia Study Group","year":"2017","unstructured":"International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol\/L (54 mg\/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017;40:155\u20137.","journal-title":"Diabetes Care"},{"key":"1423_CR32","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s11136-012-0234-3","volume":"22","author":"M Brod","year":"2013","unstructured":"Brod M, Pohlman B, Wolden M, Christensen T. Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being. Qual Life Res. 2013;22:997\u20131004.","journal-title":"Qual Life Res"},{"key":"1423_CR33","doi-asserted-by":"publisher","first-page":"A481","DOI":"10.1016\/j.jval.2011.08.1357","volume":"14","author":"JB Gruenberger","year":"2011","unstructured":"Gruenberger JB, Bader G, Benford M, Pike J. PDB54 HRQoL and clinical impact of mild patient-reported hypoglycaemic episodes in five european countries: extent of agreement between physician- and patient-reported hypoglycaemic episodes. Value Health. 2011;14:A481.","journal-title":"Value Health"},{"key":"1423_CR34","first-page":"530","volume":"9","author":"KV Allen","year":"2003","unstructured":"Allen KV, Frier BM. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2003;9:530\u201343.","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"1423_CR35","first-page":"66","volume":"5","author":"MJU Pedersen-Bjergaard","year":"2015","unstructured":"Pedersen-Bjergaard MJU. Self-reported frequency and impact of non-severe hypoglycemic events in insulin-treated diabetic patients in Denmark. Diabetes Manag. 2015;5:66\u201377.","journal-title":"Diabetes Manag"},{"key":"1423_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/0145721714529608","volume":"40","author":"SV Edelman","year":"2014","unstructured":"Edelman SV, Blose JS. The impact of nocturnal hypoglycemia on clinical and cost-related issues in patients with type 1 and type 2 diabetes. Diabetes Educ. 2014;40:269\u201379.","journal-title":"Diabetes Educ"},{"key":"1423_CR37","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jval.2011.02.001","volume":"14","author":"M Brod","year":"2011","unstructured":"Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health J Int Soc Pharmacoecon Outcomes Res. 2011;14:665\u201371.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"key":"1423_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/dmrr.377","volume":"19","author":"U Pedersen-Bjergaard","year":"2003","unstructured":"Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev. 2003;19:232\u201340.","journal-title":"Diabetes Metab Res Rev"},{"key":"1423_CR39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/dmrr.482","volume":"20","author":"U Pedersen-Bjergaard","year":"2004","unstructured":"Pedersen-Bjergaard U, Pramming S, Heller SR, et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev. 2004;20:479\u201386.","journal-title":"Diabetes Metab Res Rev"},{"key":"1423_CR40","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jdiacomp.2009.07.006","volume":"24","author":"T H\u00f8i-Hansen","year":"2010","unstructured":"H\u00f8i-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B. Classification of hypoglycemia awareness in people with type 1 diabetes in clinical practice. J Diabetes Complic. 2010;24:392\u20137.","journal-title":"J Diabetes Complic"},{"key":"1423_CR41","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2337\/diacare.17.7.697","volume":"17","author":"AE Gold","year":"1994","unstructured":"Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994;17:697\u2013703.","journal-title":"Diabetes Care"},{"key":"1423_CR42","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2337\/diacare.18.4.517","volume":"18","author":"WL Clarke","year":"1995","unstructured":"Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care. 1995;18:517\u201322.","journal-title":"Diabetes Care"},{"key":"1423_CR43","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/sim.5947","volume":"33","author":"H Zhu","year":"2014","unstructured":"Zhu H, Lakkis H. Sample size calculation for comparing two negative binomial rates. Stat Med. 2014;33:376\u201387.","journal-title":"Stat Med"},{"key":"1423_CR44","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1185\/03007995.2015.1058252","volume":"31","author":"L Landstedt-Hallin","year":"2015","unstructured":"Landstedt-Hallin L. Changes in HbA1c, insulin dose and incidence of hypoglycemia in patients with type 1 diabetes after switching to insulin degludec in an outpatient setting: an observational study. Curr Med Res Opin. 2015;31:1487\u201393.","journal-title":"Curr Med Res Opin"},{"key":"1423_CR45","unstructured":"Ratzki-Leewing A, Harris S, Ryan B, Zou G. Real-world estimates of severe hypoglycaemia and associated healthcare utilisation in the US: baseline results of the iNPHORM study. EASD. 2020; (Abstract 750)."},{"key":"1423_CR46","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2337\/diacare.10.5.617","volume":"10","author":"DJ Cox","year":"1987","unstructured":"Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care. 1987;10:617\u201321.","journal-title":"Diabetes Care"},{"key":"1423_CR47","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3111\/13696998.2011.610852","volume":"14","author":"C Fidler","year":"2011","unstructured":"Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011;14:646\u201355.","journal-title":"J Med Econ"},{"key":"1423_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2337\/dc13-1154","volume":"37","author":"J Lawton","year":"2014","unstructured":"Lawton J, Rankin D, Elliott J, et al. Experiences, views, and support needs of family members of people with hypoglycemia unawareness: interview study. Diabetes Care. 2014;37:109\u201315.","journal-title":"Diabetes Care"},{"key":"1423_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3430","volume":"37","author":"E Renard","year":"2021","unstructured":"Renard E, Ikegami H, Daher Vianna AG, et al. The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM. Diabetes Metab Res Rev. 2021;37: e3430.","journal-title":"Diabetes Metab Res Rev"},{"key":"1423_CR50","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","volume":"28","author":"M Peyrot","year":"2005","unstructured":"Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673\u20139.","journal-title":"Diabetes Care"},{"key":"1423_CR51","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1177\/0145721709345773","volume":"35","author":"RR Rubin","year":"2009","unstructured":"Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ. 2009;35:1014\u201322.","journal-title":"Diabetes Educ"},{"key":"1423_CR52","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/1753-0407.12080","volume":"6","author":"G Dailey","year":"2014","unstructured":"Dailey G, Aurand L, Stewart J, Ameer B, Zhou R. Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus. J Diabetes. 2014;6:176\u201383.","journal-title":"J Diabetes"},{"key":"1423_CR53","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","volume":"135","author":"LS Phillips","year":"2001","unstructured":"Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825\u201334.","journal-title":"Ann Intern Med"},{"key":"1423_CR54","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3949\/ccjm.71.4.335","volume":"71","author":"I Gabriely","year":"2004","unstructured":"Gabriely I, Shamoon H. Hypoglycemia in diabetes: common, often unrecognized. Cleve Clin J Med. 2004;71:335\u201342.","journal-title":"Cleve Clin J Med"},{"key":"1423_CR55","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/dom.12927","volume":"19","author":"D Mauricio","year":"2017","unstructured":"Mauricio D, Meneghini L, Seufert J, et al. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017;19:1155\u201364.","journal-title":"Diabetes Obes Metab"},{"key":"1423_CR56","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","volume":"281","author":"RC Turner","year":"1999","unstructured":"Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005\u201312.","journal-title":"JAMA"},{"key":"1423_CR57","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/j.1464-5491.2005.01644.x","volume":"22","author":"M Peyrot","year":"2005","unstructured":"Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE (2005) Psychosocial problems and barriers to improved diabetes management: results of the cross-national diabetes attitudes, wishes and needs (DAWN) study. Diabet Med. 2005;22:1379\u20131385.","journal-title":"Diabet Med"},{"key":"1423_CR58","unstructured":"Centers for Disease Control and Prevention. Overweight and obesity: data and statistics. Atlanta (GA): Centers for Disease Control and Prevention; 2020."},{"key":"1423_CR59","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00228-007-0277-5","volume":"63","author":"A Kozyrskyj","year":"2007","unstructured":"Kozyrskyj A, Raymond C, Racher A. Characterizing early prescribers of newly marketed drugs in Canada: a population-based study. Eur J Clin Pharmacol. 2007;63:597\u2013604.","journal-title":"Eur J Clin Pharmacol"},{"key":"1423_CR60","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/1472-6963-14-469","volume":"14","author":"\u00c1 Lubl\u00f3y","year":"2014","unstructured":"Lubl\u00f3y \u00c1. Factors affecting the uptake of new medicines: a systematic literature review. BMC Health Serv Res. 2014;14:469.","journal-title":"BMC Health Serv Res"},{"key":"1423_CR61","unstructured":"HEDIS measurement year 2023 volume 2: technical specifications for health plans. National Committee for Quality Assurance. 2022."},{"key":"1423_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s13300-016-0157-z","volume":"7","author":"L Elliott","year":"2016","unstructured":"Elliott L, Fidler C. Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes. Diabet Ther. 2016;7:45\u201360","journal-title":"Diabet Ther"},{"key":"1423_CR63","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1615692","volume":"377","author":"SP Marso","year":"2017","unstructured":"Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723\u201332.","journal-title":"N Engl J Med"},{"key":"1423_CR64","unstructured":"Zhou FL, Ye F, Gupta V, et al. 986-P: older adults with type 2 diabetes (T2D) experience less hypoglycemia when switching to insulin glargine 300 U\/mL (Gla- 300) vs other basal insulins (DELIVER 3 Study). Poster Am. Diabetes Assoc. Conf. 2017."},{"key":"1423_CR65","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s11606-010-1389-7","volume":"25","author":"U Sarkar","year":"2010","unstructured":"Sarkar U, Karter AJ, Liu JY, Moffet HH, Adler NE, Schillinger D. Hypoglycemia is more common among type 2 diabetes patients with limited health literacy: the Diabetes Study of Northern California (DISTANCE). J Gen Intern Med. 2010;25:962\u20138.","journal-title":"J Gen Intern Med"},{"key":"1423_CR66","first-page":"541","volume":"29","author":"CH Sherrill","year":"2023","unstructured":"Sherrill CH, Lee S. Prevalence, characteristics, and health-related quality of life of continuous glucose monitoring use according to the Behavioral Risk Factor Surveillance System 2014\u20132020. J Manag Care Spec Pharm. 2023;29:541\u20139.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-023-01423-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-023-01423-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-023-01423-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T10:43:19Z","timestamp":1687862599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-023-01423-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,3]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1423"],"URL":"https:\/\/doi.org\/10.1007\/s13300-023-01423-3","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,3]]},"assertion":[{"value":"11 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}